We discuss the potential for additional avenues of therapeutic intervention with studies of ACE2 in hypertension and diabetes, and BAG3 in cardiomyopathies, and the need to understand the relationships with NT-proBNP for diagnostic purposes in stratified groups of patients. This evidence concerns the gene ACE2 and cardiomyopathy.